Search

Your search keyword '"Fustier, P."' showing total 116 results

Search Constraints

Start Over You searched for: Author "Fustier, P." Remove constraint Author: "Fustier, P."
116 results on '"Fustier, P."'

Search Results

2. The synchronous generator of low reversibility.Axial magnetic flow option

3. Surgimiento de las máquinas eléctricas y la exposición de paris 1889

6. Common gardens in teosintes reveal the establishment of a syndrome of adaptation to altitude.

7. Entre didactique des langues et pratiques théâtrales, un consensus à trouver

9. Data Monitoring Committees and clinical trials: From scientific justification to organisation

10. Enrichment of cheese with vitamin D3 and vegetable omega-3

11. Faster clinical recovery with ensovibep compared to placebo in patients with mild-to-moderate COVID-19: interim results from the EMPATHY Phase 2 trial

12. Correction: Asymptomatic aortic stenosis: An assessment of patients' and of their general practitioners' knowledge, after an indexed specialized assessment in community practice.

13. Asymptomatic aortic stenosis: An assessment of patients' and of their general practitioners' knowledge, after an indexed specialized assessment in community practice.

14. Enrichment of cheese with bioactive lipophilic compounds

15. Insulin, CCAAT/enhancer-binding proteins and lactate regulate the human 11β-hydroxysteroid dehydrogenase type 2 gene expression in colon cancer cell lines.

17. MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI‐CD20 VERSUS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA.

23. AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2 ) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS

24. PS1252 PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO (AUGMENT)

25. PS1262 POST HOC ANALYSIS OF THE AUGMENT PHASE III RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA

26. POST HOC ANALYSES OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA WHO RECEIVED LENALIDOMIDE PLUS RITUXIMAB (R2 ) VS RITUXIMAB/PLACEBO (AUGMENT)

27. AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2 ) THAN RITUXIMAB/PLACEBO

28. HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN RELAPSED/REFRACTORY (R/R) INDOLENT NHL IN THE PHASE 3 AUGMENT TRIAL OF RITUXIMAB (R) PLUS LENALIDOMIDE (R2 ) VERSUS R PLUS PLACEBO

29. Survival in food systems of Lactobacillus rhamnosus R011 microentrapped in whey protein gel particles

31. [(dcpp)Ni(η2-Arene)] Precursors: Synthesis, Reactivity, and Catalytic Application to the Suzuki–Miyaura Reaction

33. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.

34. Essai monocentrique prospectif randomisé contrôlé et sans insu de la mobilité lombo-pelvi-fémorale chez les sujets âgés lors du pédalage assis sur une selle ordinaire ou une assise articulée Inawa®

37. Tislelizumab, an Anti-PD1 Antibody, in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma in Tirhol Bgb-A317-210: A Prospective Multicenter Lysa Phase 2 Study Conducted in Western Countries

38. HEALTH‐RELATED QUALITY OF LIFE (HRQoL) IN RELAPSED/REFRACTORY (R/R) INDOLENT NHL IN THE PHASE 3 AUGMENT TRIAL OF RITUXIMAB (R) PLUS LENALIDOMIDE (R2) VERSUS R PLUS PLACEBO.

39. AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO.

45. Enrichment of cheese with vitamin D3 and vegetable omega-3.

48. Comité de surveillance indépendant dans les essais cliniques : de la justification scientifique à l’organisation

49. Enrichment of cheese with bioactive lipophilic compounds.

Catalog

Books, media, physical & digital resources